Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pazopanib hydrochloride in metastatic melanoma unsuitable for surgical removal has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma Ajcc V6 and V7
• Melanoma

Drugs mentioned

• Pazopanib hydrochloride (pazopanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 2 | Status: COMPLETED | Results posted: 2014-01-21